ANAVEX LIFE SCIENCES CORP. Logo

ANAVEX LIFE SCIENCES CORP.

Clinical-stage biopharmaceutical company developing therapeutics for CNS disorders.

AVXL | US

Overview

Corporate Details

ISIN(s):
US0327973006
LEI:
Country:
United States of America
Address:
630 5TH AVENUE, 10111 NEW YORK

Description

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for central nervous system (CNS) disorders. The company develops targeted drug candidates for neurodegenerative and neurodevelopmental diseases, including Alzheimer's disease, Parkinson's disease, and Rett syndrome. Anavex's approach is centered on precision medicine, utilizing small molecule drugs designed to restore cellular homeostasis. Its lead investigational compound, blarcamesine (ANAVEX®2-73), is an orally available sigma-1 receptor (S1R) agonist being evaluated for its potential to treat a range of neurological conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-11-25 22:31
FORM 10-K
English ZIP 3.5 MB
2025-11-25 13:30
FORM 8-K
English ZIP 101.8 KB
2025-11-14 13:42
FORM 8-K
English ZIP 79.8 KB
2025-10-04 02:42 English ZIP 7.3 KB
2025-10-04 02:41 English ZIP 7.3 KB
2025-09-13 01:00 English ZIP 7.6 KB
2025-08-22 23:30 English ZIP 7.2 KB
2025-08-22 23:30 English ZIP 7.3 KB
2025-08-12 22:08
FORM 10-Q
English ZIP 1005.4 KB
2025-07-26 01:26
FORM 8-K
English ZIP 243.1 KB
2025-07-25 22:48
FORM 424B5
English ZIP 185.5 KB
2025-07-24 06:15 English ZIP 5.2 KB
2025-07-21 21:39 English ZIP 6.9 KB
2025-07-21 17:36 English ZIP 57.8 KB
2025-07-14 22:30
FORM S-3
English ZIP 85.3 KB

Automate Your Workflow. Get a real-time feed of all ANAVEX LIFE SCIENCES CORP. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ANAVEX LIFE SCIENCES CORP.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ANAVEX LIFE SCIENCES CORP. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.